无乳链球菌阳性对照 返回列表页

美国Seracare无乳链球菌阳性对照

广州健仑生物科技有限公司

广州健仑长期供应各种生物原料，主要代理品牌：美国Seracare、西班牙Certest、美国Fuller等等。

主要产品包括各种标准品、阳性对照品、阳性质控品、单克隆抗原抗体。

其中常见的有：弓形虫病、西尼罗河病毒、类风湿因子、疟疾、麻疹、莱姆病、百日咳杆菌、大肠杆菌、鼠伤寒沙门氏菌、李斯特菌等阳性对照品。

美国Seracare无乳链球菌阳性对照

我司还提供其它进口或国产试剂盒：登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

欢迎咨询

欢迎咨询2042552662

【Seracare产品介绍】

美国Seracare

文章的通讯作者Benz指出，我们组织中大部分是由许多不同类型的上皮细胞和非上皮细胞组成，“这项抗原抗体性的基因组研究不仅挑战了基于组织类型的现有癌症分类系统，而且还提供了能用于进一步研究的大量新数据来源，以及能用于区分每种新描述癌症类型的分子特征整体列表，”Benz说，“比如说膀胱癌能重新被分成几种不同的癌症类型，每一种都具有不同的临床表征，这就有助于解释对看似相同的癌症类型进行相同的全身疗法治疗，为什么患者往往反应截然不同”。
这一研究组发现在十个癌症患者中至少有一个能通过这种新系统分类到不同的癌症类型中，而且Benz认为如果他们下一轮进行更多的样品，和肿瘤类型的分析，将会有更多的肿瘤需要重新分类，他预计下一轮将进行超过20种不同肿瘤类型的分析。
“考虑到这种多平台类型基因组分析的潜力，我们还只是分析了冰山的一角。未来可能还有多达30%或 50%的癌症需要被重新归类”。
在这项研究中，zui引人注目的发现就是膀胱癌和抗原抗体癌方面的成果，至少有三个不同亚型的膀胱癌需要重新分类：一种是无法与肺腺癌区分开来的亚型，一种是与起源自头部，颈部和肺部的鳞状上皮细胞癌很相似的亚型。
这项研究也指出和证实了抗原抗体癌类型中已知的差异，而且还揭示出了新的令人惊讶的发现——基底样抗原抗体癌实际上是一类新癌症类型。
基底样抗原抗体癌(Basal-like breast cancers)通常称为三阴性抗原抗体癌(triple-negative breast cancer)，是一种特别具有侵袭性，并致命的癌症。“即使这些基底样癌症出现在抗原抗体中，但在分子水平上它们与卵巢癌和鳞状上皮细胞起源的癌症更为相似，”Yau说。
Benz认为这一研究将能被用于临床试验设计，尤其是希望能通过肿瘤基因组重分类，寻找新的治疗方法的患者，“虽然需要后续的研究来验证，并完善这一新提出的癌症分类系统，但是这项研究zui终将能为个性化癌症医疗时代的到来，奠定基础生物学基础。”
尽管目前正在开发各种化合物对抗癌症，但它们都具有严重的副作用。此外，肿瘤能够对这些化合物产生耐药。
为了抵消上述两个缺点，科学家们设计了一种基于肽的新疗法，利用黄蜂毒液中的多肽，作为预防抗原抗体癌的潜在新方法。
这种肽具有在细胞质膜形成孔的能力，并穿透进入癌细胞，或诱导癌细胞坏死或触发凋亡，zui后导致癌细胞死亡。

美国Seracare

我司还提供其它进口或国产试剂盒：登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、食品安全、化妆品检测、药物滥用检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

想了解更多的产品及服务请扫描下方二维码：

【公司名称】 广州健仑生物科技有限公司
【市场部】    杨永汉

【】 
【腾讯  】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室

Benz, the article's author, notes that most of our tissue is made up of many different types of epithelial cells and non-epithelial cells. "This antigen-antibody genomic study not only challenged existing cancer classification systems based on tissue type but also Provides a host of new sources of data that can be used for further research, as well as a comprehensive list of molecular features that can be used to differentiate each newly described cancer type, "says Benz." For example, bladder cancer can be subdivided into several different cancer types, Each has a different clinical manifestation, which helps to explain why patients often respond differently to seemingly identical types of cancer for the same systemic therapy. "
The team found that at least one out of ten cancer patients could be classified into different cancer types by this new system, and that Benz believes that if they do more samples in the next round, and tumor types will be analyzed There are more tumors that need to be reclassified, and he expects the next round of analysis to be performed on more than 20 different tumor types.
"Given the potential of this multiplatform type of genomic analysis, we're still just analyzing the tip of the iceberg, and perhaps as many as 30 or 50% of cancers need to be reclassified in the future."
The most striking finding in this study is the result of bladder cancer and antigen-antibody cancers that require reclassification of at least three different subtypes of bladder cancer: one that is indistinguishable from lung adenocarcinoma One that is very similar to squamous cell carcinoma, which originates from the head, neck and lung.
This study also points to and confirms the known differences in antigen-antibody cancer types and reveals new and surprising findings that basal-like antigen-antibody cancer is actually a new class of cancer.
Basal-like breast cancers, commonly known as triple-negative breast cancers, are a particularly aggressive and deadly cancer. "Even though these basal-like cancers are present in antigen-antibodies, they are more like molecularly cancers of ovarian and squamous cell origin," Yau said.
Benz believes the study will be used in clinical trial design, especially in patients wishing to reclassify the tumor genome for new treatments, "although follow-up studies are needed to validate and refine the newly proposed cancer classification System, but the research will ultimay lay the foundations of basic biology for the advent of the personalized cancer care era. "
Although various compounds are currently being developed to combat cancer, they all have serious side effects. In addition, tumors can become resistant to these compounds.
In order to counteract the above two drawbacks, scientists have designed a new peptide-based therapy that uses the polypeptide in wasp venom as a potential new method of preventing antigen-antibody cancer.
This peptide has the ability to form pores in the plasma membrane and penetrates into cancer cells, induces necrosis or triggers apoptosis in cancer cells, and ultimay leads to the death of cancer cells.